Stockscreener 앱 받기
9.03
0.11%
-0.010
시간 외 거래:
8.99
-0.04
-0.44%
전일 마감가:
$9.04
열려 있는:
$8.95
하루 거래량:
1.44M
Relative Volume:
1.16
시가총액:
$1.29B
수익:
$175.51M
순이익/손실:
$-78.02M
주가수익비율:
-17.04
EPS:
-0.53
순현금흐름:
$-34.18M
1주 성능:
-3.63%
1개월 성능:
+9.59%
6개월 성능:
+65.38%
1년 성능:
+1.35%
1일 변동 폭
$8.92
$9.23
1주일 범위
$8.92
$9.76
52주 변동 폭
$4.71
$10.67
Aurinia Pharmaceuticals Inc Stock (AUPH) Company Profile
명칭
Aurinia Pharmaceuticals Inc
전화
250-744-2487
주소
#140, 14315 - 118 AVENUE, EDMONTON, BC
AUPH을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
AUPH
Aurinia Pharmaceuticals Inc
|
9.03 | 1.29B | 175.51M | -78.02M | -34.18M | -0.53 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Aurinia Pharmaceuticals Inc Stock (AUPH) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2022-11-04 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2022-05-05 | 재개 | Cantor Fitzgerald | Overweight |
| 2021-12-10 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2021-10-28 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2021-01-25 | 재확인 | H.C. Wainwright | Buy |
| 2020-11-03 | 재확인 | H.C. Wainwright | Buy |
| 2020-06-17 | 개시 | BTIG Research | Buy |
| 2020-05-05 | 개시 | Cowen | Outperform |
| 2020-01-10 | 개시 | Jefferies | Buy |
| 2019-12-16 | 재확인 | H.C. Wainwright | Buy |
| 2018-03-16 | 재확인 | Cantor Fitzgerald | Overweight |
| 2018-02-08 | 개시 | RBC Capital Mkts | Outperform |
| 2017-10-30 | 재확인 | H.C. Wainwright | Buy |
| 2017-05-18 | 재확인 | H.C. Wainwright | Buy |
| 2017-04-11 | 개시 | Cantor Fitzgerald | Overweight |
| 2017-03-22 | 재확인 | FBR & Co. | Outperform |
| 2016-12-30 | 재확인 | H.C. Wainwright | Buy |
| 2016-08-17 | 재확인 | H.C. Wainwright | Buy |
| 2016-06-30 | 개시 | H.C. Wainwright | Buy |
| 2015-05-08 | 개시 | MLV & Co | Buy |
모두보기
Aurinia Pharmaceuticals Inc 주식(AUPH)의 최신 뉴스
(AUPH) On The My Stocks Page - Stock Traders Daily
Layoff Tracker: Editas Will Cut 60% of Staff - BioSpace
Short Interest in Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Declines By 9.6% - MarketBeat
Aurinia Pharmaceuticals (NASDAQ:AUPH) Rating Lowered to "Buy" at StockNews.com - MarketBeat
Charles Schwab Investment Management Inc. Grows Position in Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) - MarketBeat
Aurinia Pharma Surges Pre-Market After Director Kevin Tang Discloses $10M Stock Buy: Retail Confidence Spikes - MSN
Exploring Three High Growth Tech Stocks In The United States - Simply Wall St
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Held Back By Insufficient Growth Even After Shares Climb 25% - Simply Wall St
Implied Volatility Surging for Aurinia Pharmaceuticals (AUPH) Stock Options - MSN
Aurinia Pharma stock hits 52-week high at $9.76 - Investing.com
Aurinia Pharma stock hits 52-week high at $9.76 By Investing.com - Investing.com UK
Kevin Tang buys $10.82 million in Aurinia Pharmaceuticals shares - Investing.com India
Kevin Tang buys $10.82 million in Aurinia Pharmaceuticals shares By Investing.com - Investing.com Australia
(AUPH) Investment Analysis - Stock Traders Daily
While institutions own 40% of Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH), retail investors are its largest shareholders with 52% ownership - Yahoo Finance
We Might See A Profit From Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Soon - Simply Wall St
PDT Partners LLC Buys 130,204 Shares of Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) - MarketBeat
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Shares Sold by Algert Global LLC - MarketBeat
Connor Clark & Lunn Investment Management Ltd. Invests $3.33 Million in Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) - MarketBeat
Aurinia Pharmaceuticals (AUPH) Q3 Earnings and Revenues Beat Estimates - MSN
Aurinia Commends 2024 Updated ACR Guidelines for Screening, Treatment, and Management of Lupus Nephritis - sharewise
Aurinia's LUPKYNIS Named First-Line Treatment in 2024 ACR Lupus Nephritis Guidelines - StockTitan
(AUPH) Technical Pivots with Risk Controls - Stock Traders Daily
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Position Reduced by GSA Capital Partners LLP - MarketBeat
Aurinia Presents New Data Underscoring Critical Importance of Earlier Lupus Nephritis Detection and Intervention and Value of LUPKYNIS® in Managing LN at American College of Rheumatology Convergence 2024 - sharewise
Aurinia Pharmaceuticals Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
ARMISTICE CAPITAL, LLC's Strategic Reduction in Aurinia Pharmace - GuruFocus.com
Aurinia to Participate in Jefferies London Healthcare Conference - sharewise
Aurinia Pharmaceuticals Engages at London Conference - TipRanks
Aurinia Pharmaceuticals director Karen Smith sells $44,181 in stock - Investing.com India
Aurinia Pharmaceuticals director Karen Smith sells $44,181 in stock By Investing.com - Investing.com Nigeria
Aurinia Pharmaceuticals director sells shares valued at $38,415 - Investing.com India
Aurinia Pharmaceuticals director sells shares valued at $38,415 By Investing.com - Investing.com Canada
Aurinia Pharmaceuticals (NASDAQ:AUPH) Upgraded at StockNews.com - Defense World
Aurinia Pharmaceuticals Third Quarter 2024 Earnings: Beats Expectations - Simply Wall St
Aurinia stock jumps 14% on Q3 earnings, restructuring announcement - MSN
Aurinia Pharmaceuticals Inc (AUPH) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Aurinia Pharmaceuticals Inc 주식 (AUPH) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| TANG KEVIN | Director |
Dec 06 '24 |
Buy |
9.01 |
400,000 |
3,604,000 |
7,929,500 |
| TANG KEVIN | Director |
Dec 05 '24 |
Buy |
8.91 |
300,000 |
2,673,000 |
7,529,500 |
| Bailey Jeffrey Allen | Director |
Nov 11 '24 |
Sale |
8.43 |
4,557 |
38,416 |
13,356 |
| Smith Karen L. | Director |
Nov 11 '24 |
Sale |
8.43 |
5,241 |
44,182 |
12,672 |
| Habig Scott Michael | Chief Commercial Officer |
Aug 06 '24 |
Sale |
5.31 |
18,249 |
96,902 |
456,338 |
| Balakrishnan Brinda | Director |
May 21 '24 |
Sale |
5.74 |
520 |
2,985 |
17,523 |
| Billen Daniel | Director |
May 21 '24 |
Sale |
5.74 |
5,252 |
30,146 |
28,141 |
| Jayne David R.W. | Director |
May 21 '24 |
Sale |
5.74 |
4,946 |
28,390 |
44,364 |
| Leversage Jill | Director |
May 21 '24 |
Sale |
5.74 |
5,610 |
32,201 |
12,918 |
| MacKay-Dunn R. Hector | Director |
May 21 '24 |
Sale |
5.74 |
5,630 |
32,316 |
18,595 |
2.88%
2.65%
자본화:
|
볼륨(24시간):